Tuberculosis drug discovery in the CRISPR era

Prediction of ultra-high-order antibiotic combinations based on pairwise interactions

(2019) Itay Katzir et al.   PLoS Computational Biology

Large-scale chemical–genetics yields new M. tuberculosis inhibitor classes

(2019) Eachan O. Johnson et al.   NATURE

Impact of immunopathology on the antituberculous activity of pyrazinamide

(2018) Landry Blanc et al.   JOURNAL OF EXPERIMENTAL MEDICINE

TnSeq of Mycobacterium tuberculosis clinical isolates reveals strain-specific antibiotic liabilities

(2018) Allison F. Carey et al.   PLoS Pathogens

Bacterial Factors That Predict Relapse after Tuberculosis Therapy

(2018) Roberto Colangeli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application

(2017) Christopher A. Kerantzas et al.   mBio

Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time

(2017) Bai-Yu Lee et al.   Nature Communications

Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform

(2017) Jeremy M. Rock et al.   Nature Microbiology

Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis

(2017) Murat Cokol et al.   Science Advances

A Comprehensive, CRISPR-based Functional Analysis of Essential Genes in Bacteria

(2016) Jason M. Peters et al.   CELL

Validation of CoaBC as a Bactericidal Target in the Coenzyme A Pathway of Mycobacterium tuberculosis

(2016) Joanna C. Evans et al.   ACS Infectious Diseases

Network Architecture Predisposes an Enzyme to Either Pharmacologic or Genetic Targeting

(2016) Karin J. Jensen et al.   Cell Systems

Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution

(2015) Tobias Bollenbach   CURRENT OPINION IN MICROBIOLOGY

The association between sterilizing activity and drug distribution into tuberculosis lesions

(2015) Brendan Prideaux et al.   NATURE MEDICINE

Genetic Approaches to Facilitate Antibacterial Drug Development

(2015) Dirk Schnappinger   Cold Spring Harbor Perspectives in Medicine

Tuberculosis drug discovery in the post-post-genomic era

(2014) Benoit Lechartier et al.   EMBO Molecular Medicine

DNA interrogation by the CRISPR RNA-guided endonuclease Cas9

(2014) Samuel H. Sternberg et al.   NATURE

The discovery of first-in-class drugs: origins and evolution

(2014) Jörg Eder et al.   NATURE REVIEWS DRUG DISCOVERY

Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression

(2013) Lei S. Qi et al.   CELL

Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis

(2013) Lluís Ballell et al.   ChemMedChem

Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans

(2013) Iñaki Comas et al.   NATURE GENETICS

Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system

(2013) David Bikard et al.   NUCLEIC ACIDS RESEARCH

Dynamic Persistence of Antibiotic-Stressed Mycobacteria

(2013) Y. Wakamoto et al.   SCIENCE

Targeting Persisters for Tuberculosis Control

(2012) Ying Zhang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pathway-Selective Sensitization of Mycobacterium tuberculosis for Target-Based Whole-Cell Screening

(2012) Garth L. Abrahams et al.   CHEMISTRY & BIOLOGY

A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity

(2012) M. Jinek et al.   SCIENCE

Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism

(2011) Kristin N. Adams et al.   CELL

Depletion of antibiotic targets has widely varying effects on growth

(2011) J.-R. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy

(2010) Kevin Pethe et al.   Nature Communications

Short motif sequences determine the targets of the prokaryotic CRISPR defence system

(2009)   MICROBIOLOGY-SGM